Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1981 Oct;40(5):455–461. doi: 10.1136/ard.40.5.455

Antiprostaglandin synthetase activity of nonsteroidal anti-inflammatory drugs and gastrointestinal micro-bleeding: a comparison of flurbiprofen with benoxaprofen.

A C Yeung Laiwah, T E Hilditch, P W Horton, J A Hunter
PMCID: PMC1000780  PMID: 6796008

Abstract

By using 51Cr-labelled erythrocytes and 141Ce-labelled microspheres to correct for daily variations in faecal output, gastrointestinal microbleeding was measured in hospital patients with rheumatoid arthritis before and after administration of 2 propionic acid derivatives. These were flurbiprofen and benoxaprofen, respectively a potent and a weak prostaglandin synthetase inhibitor. Increased faecal blood loss occurred consistently with flurbiprofen and not with benoxaprofen. Our results provide indirect evidence for the cytoprotective effect of prostaglandins on the gastrointestinal mucosa in man. The quantitative correlation between faecal occult blood loss as measured by the above techniques and the Haemoccult slide test is also discussed.

Full text

PDF
455

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Caruso I., Bianchi Porro G. Gastroscopic evaluation of anti-inflammatory agents. Br Med J. 1980 Jan 12;280(6207):75–78. doi: 10.1136/bmj.280.6207.75. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Cashin C. H., Dawson W., Kitchen E. A. The pharmacology of benoxaprofen (2-[4-chlorophenyl]-alpha-methyl-5-benzoxazole acetic acid), LRCL 3794, a new compound with antiinflammatory activity apparently unrelated to inhibition of prostaglandin synthesis. J Pharm Pharmacol. 1977 Jun;29(6):330–336. doi: 10.1111/j.2042-7158.1977.tb11330.x. [DOI] [PubMed] [Google Scholar]
  3. Chernish S. M., Rosenak B. D., Brunelie R. L., Crabtree R. Comparison of gastrointestinal effects of aspirin and fenoprofen. A double blind crossover study. Arthritis Rheum. 1979 Apr;22(4):376–383. doi: 10.1002/art.1780220410. [DOI] [PubMed] [Google Scholar]
  4. Cohen M. M. Mucosal cytoprotection by prostaglandin E2. Lancet. 1978 Dec 9;2(8102):1253–1254. doi: 10.1016/s0140-6736(78)92124-4. [DOI] [PubMed] [Google Scholar]
  5. Croker J. R., Cotton P. B., Boyle A. C., Kinsella P. Cimetidine for peptic ulcer in patients with arthritis. Ann Rheum Dis. 1980 Jun;39(3):275–278. doi: 10.1136/ard.39.3.275. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Crook D., Collins A. J., Rose A. J. A comparison of the effect of flurbiprofen on prostaglandin synthetase from human rheumatoid synovium and enzymatically active animal tissues. J Pharm Pharmacol. 1976 Jun;28(6):535–535. doi: 10.1111/j.2042-7158.1976.tb02787.x. [DOI] [PubMed] [Google Scholar]
  7. Evans G. H., Shand D. G. Disposition of propranolol. V. Drug accumulation and steady-state concentrations during chronic oral administration in man. Clin Pharmacol Ther. 1973 Jul-Aug;14(4):487–493. doi: 10.1002/cpt1973144part1487. [DOI] [PubMed] [Google Scholar]
  8. Goulston K., Cooke A. R. Alcohol, aspirin, and gastrointestinal bleeding. Br Med J. 1968 Dec 14;4(5632):664–665. doi: 10.1136/bmj.4.5632.664. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Greegor D. H. Occult blood testing for detection of asymptomatic colon cancer. Cancer. 1971 Jul;28(1):131–134. doi: 10.1002/1097-0142(197107)28:1<131::aid-cncr2820280125>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  10. Jick H., Porter J. Drug-induced gastrointestinal bleeding. Report from the Boston Collaborative Drug Surveillance Program, Boston University Medical Center. Lancet. 1978 Jul 8;2(8080):87–89. doi: 10.1016/s0140-6736(78)91396-x. [DOI] [PubMed] [Google Scholar]
  11. Johansson C., Kollberg B., Nordemar R., Samuelson K., Bergström S. Protective effect of prostaglandin E2 in the gastrointestinal tract during indomethacin treatment of rheumatic diseases. Gastroenterology. 1980 Mar;78(3):479–483. [PubMed] [Google Scholar]
  12. Kent T. H., Cardelli R. M., Stamler F. W. Small intestinal ulcers and intestinal flora in rats given indomethacin. Am J Pathol. 1969 Feb;54(2):237–249. [PMC free article] [PubMed] [Google Scholar]
  13. Levy M. Aspirin use in patients with major upper gastrointestinal bleeding and peptic-ulcer disease. A report from the Boston Collaborative Drug Surveillance Program, Boston University Medical Center. N Engl J Med. 1974 May 23;290(21):1158–1162. doi: 10.1056/NEJM197405232902102. [DOI] [PubMed] [Google Scholar]
  14. Loebl D. H., Craig R. M., Culic D. D., Ridolfo A. S., Falk J., Schmid F. R. Gastrointestinal blood loss. Effect of aspirin, fenoprofen, and acetaminophen in rheumatoid arthritis as determined by sequential gastroscopy and radioactive fecal markers. JAMA. 1977 Mar 7;237(10):976–981. doi: 10.1001/jama.237.10.976. [DOI] [PubMed] [Google Scholar]
  15. Miller T. A., Jacobson E. D. Gastrointestinal cytoprotection by prostaglandins. Gut. 1979 Jan;20(1):75–87. doi: 10.1136/gut.20.1.75. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Robert A. Antisecretory, antiulcer, cytoprotective and diarrheogenic properties of prostaglandins. Adv Prostaglandin Thromboxane Res. 1976;2:507–520. [PubMed] [Google Scholar]
  17. Robert A., Nezamis J. E., Lancaster C., Hanchar A. J. Cytoprotection by prostaglandins in rats. Prevention of gastric necrosis produced by alcohol, HCl, NaOH, hypertonic NaCl, and thermal injury. Gastroenterology. 1979 Sep;77(3):433–443. [PubMed] [Google Scholar]
  18. Roth S. H., Boost G. An open trial of naproxen in rheumatoid arthritis patients with significant esophageal, gastric, and duodenal lesions. J Clin Pharmacol. 1975 Apr;15(4 Pt 2):378–384. doi: 10.1002/j.1552-4604.1975.tb01468.x. [DOI] [PubMed] [Google Scholar]
  19. SCOTT J. T., PORTER I. H., LEWIS S. M., DIXON A. S. Studies of gastrointestinal bleeding caused by corticosteroids, salicylates, and other analgesics. Q J Med. 1961 Apr;30:167–188. [PubMed] [Google Scholar]
  20. Silvoso G. R., Ivey K. J., Butt J. H., Lockard O. O., Holt S. D., Sisk C., Baskin W. N., Mackercher P. A., Hewett J. Incidence of gastric lesions in patients with rheumatic disease on chronic aspirin therapy. Ann Intern Med. 1979 Oct;91(4):517–520. doi: 10.7326/0003-4819-91-4-517. [DOI] [PubMed] [Google Scholar]
  21. Stroehlein J. R., Fairbanks V. F., McGill D. B., Go V. L. Hemoccult detection of fecal occult blood quantitated by radioassay. Am J Dig Dis. 1976 Oct;21(10):841–844. doi: 10.1007/BF01072074. [DOI] [PubMed] [Google Scholar]
  22. Vane J. R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971 Jun 23;231(25):232–235. doi: 10.1038/newbio231232a0. [DOI] [PubMed] [Google Scholar]
  23. Wax J., Clinger W. A., Varner P., Bass P., Winder C. V. Relationship of the enterohepatic cycle to ulcerogenesis in the rat small bowel with flufenamic acid. Gastroenterology. 1970 Jun;58(6):772–780. [PubMed] [Google Scholar]
  24. Willkens R. F. The use of nonsteroidal anti-inflammatory agents. JAMA. 1978 Oct 6;240(15):1632–1635. [PubMed] [Google Scholar]
  25. Winawer S. J. Fecal occult blood testing. Am J Dig Dis. 1976 Oct;21(10):885–888. doi: 10.1007/BF01072082. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES